USANA Health Sciences (NYSE:USNA) Reaches New 1-Year Low – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA) reached a new 52-week low on Thursday . The company traded as low as $34.76 and last traded at $35.04, with a volume of 3078 shares. The stock had previously closed at $35.43.

Wall Street Analysts Forecast Growth

USNA has been the subject of a number of research analyst reports. DA Davidson lowered their price target on USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, July 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

USANA Health Sciences Stock Performance

The company has a 50 day moving average of $38.47 and a 200-day moving average of $43.21. The stock has a market cap of $681.80 million, a price-to-earnings ratio of 12.51, a price-to-earnings-growth ratio of 1.18 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The firm had revenue of $212.87 million for the quarter, compared to analyst estimates of $218.64 million. During the same period in the previous year, the company posted $0.89 EPS. On average, research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 EPS for the current year.

Insider Buying and Selling

In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the sale, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the sale, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,940 shares of company stock valued at $311,670. Corporate insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On USANA Health Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pzena Investment Management LLC raised its position in shares of USANA Health Sciences by 24.4% during the 2nd quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock worth $44,183,000 after acquiring an additional 191,289 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of USANA Health Sciences by 0.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 683,158 shares of the company’s stock worth $30,907,000 after acquiring an additional 3,889 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of USANA Health Sciences by 14.3% during the 2nd quarter. Pacer Advisors Inc. now owns 467,352 shares of the company’s stock worth $21,143,000 after acquiring an additional 58,597 shares in the last quarter. American Century Companies Inc. grew its stake in USANA Health Sciences by 12.3% during the 2nd quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock worth $7,229,000 after buying an additional 17,460 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in USANA Health Sciences by 2.6% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 111,492 shares of the company’s stock worth $5,407,000 after buying an additional 2,820 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.